vs
BioLineRx Ltd.（BLRX）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是BioLineRx Ltd.的2649.7倍（$805.5M vs $304.0K）。NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -1296.1%，领先1315.1%）。NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs -94.4%）。NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $-2.8M）
BioLineRx（简称BioLine）是一家专注于药物开发的上市企业，总部设立于以色列，公司股份同时在美国纳斯达克资本市场和以色列特拉维夫证券交易所挂牌交易。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
BLRX vs NBIX — 直观对比
营收规模更大
NBIX
是对方的2649.7倍
$304.0K
营收增速更快
NBIX
高出122.7%
-94.4%
净利率更高
NBIX
高出1315.1%
-1296.1%
自由现金流更多
NBIX
多$388.8M
$-2.8M
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $304.0K | $805.5M |
| 净利润 | $-3.9M | $153.7M |
| 毛利率 | 76.3% | 97.8% |
| 营业利润率 | -757.6% | 26.2% |
| 净利率 | -1296.1% | 19.1% |
| 营收同比 | -94.4% | 28.3% |
| 净利润同比 | -914.0% | 49.1% |
| 每股收益（稀释后） | $0.00 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLRXNBIX
| Q4 25 | — | $805.5M | ||
| Q3 25 | — | $794.9M | ||
| Q2 25 | $304.0K | $687.5M | ||
| Q1 25 | — | $572.6M | ||
| Q4 24 | — | $627.7M | ||
| Q3 24 | — | $622.1M | ||
| Q2 24 | $5.4M | $590.2M | ||
| Q1 24 | — | $515.3M |
净利润BLRXNBIX
| Q4 25 | — | $153.7M | ||
| Q3 25 | — | $209.5M | ||
| Q2 25 | $-3.9M | $107.5M | ||
| Q1 25 | — | $7.9M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $129.8M | ||
| Q2 24 | $484.0K | $65.0M | ||
| Q1 24 | — | $43.4M |
毛利率BLRXNBIX
| Q4 25 | — | 97.8% | ||
| Q3 25 | — | 98.2% | ||
| Q2 25 | 76.3% | 98.4% | ||
| Q1 25 | — | 98.4% | ||
| Q4 24 | — | 98.5% | ||
| Q3 24 | — | 98.7% | ||
| Q2 24 | 83.4% | 98.4% | ||
| Q1 24 | — | 98.5% |
营业利润率BLRXNBIX
| Q4 25 | — | 26.2% | ||
| Q3 25 | — | 30.1% | ||
| Q2 25 | -757.6% | 21.2% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 29.5% | ||
| Q2 24 | -107.0% | 24.6% | ||
| Q1 24 | — | 19.3% |
净利率BLRXNBIX
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 26.4% | ||
| Q2 25 | -1296.1% | 15.6% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | — | 20.9% | ||
| Q2 24 | 9.0% | 11.0% | ||
| Q1 24 | — | 8.4% |
每股收益（稀释后）BLRXNBIX
| Q4 25 | — | $1.49 | ||
| Q3 25 | — | $2.04 | ||
| Q2 25 | $0.00 | $1.06 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | — | $1.00 | ||
| Q3 24 | — | $1.24 | ||
| Q2 24 | $0.00 | $0.63 | ||
| Q1 24 | — | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.2M | $713.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $20.1M | $3.3B |
| 总资产 | $43.3M | $4.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLRXNBIX
| Q4 25 | — | $713.0M | ||
| Q3 25 | — | $340.2M | ||
| Q2 25 | $7.2M | $264.0M | ||
| Q1 25 | — | $194.1M | ||
| Q4 24 | — | $233.0M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | $9.6M | $139.7M | ||
| Q1 24 | — | $396.3M |
股东权益BLRXNBIX
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | $20.1M | $2.7B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | $13.9M | $2.5B | ||
| Q1 24 | — | $2.4B |
总资产BLRXNBIX
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | $4.3B | ||
| Q2 25 | $43.3M | $3.9B | ||
| Q1 25 | — | $3.7B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.5B | ||
| Q2 24 | $64.6M | $3.3B | ||
| Q1 24 | — | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.8M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.8M | $386.0M |
| 自由现金流率自由现金流/营收 | -914.1% | 47.9% |
| 资本支出强度资本支出/营收 | 3.6% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | — | $743.9M |
8季度趋势，按日历期对齐
经营现金流BLRXNBIX
| Q4 25 | — | $388.4M | ||
| Q3 25 | — | $227.5M | ||
| Q2 25 | $-2.8M | $102.0M | ||
| Q1 25 | — | $64.8M | ||
| Q4 24 | — | $242.5M | ||
| Q3 24 | — | $158.0M | ||
| Q2 24 | $-25.4M | $64.6M | ||
| Q1 24 | — | $130.3M |
自由现金流BLRXNBIX
| Q4 25 | — | $386.0M | ||
| Q3 25 | — | $214.3M | ||
| Q2 25 | $-2.8M | $89.5M | ||
| Q1 25 | — | $54.1M | ||
| Q4 24 | — | $235.2M | ||
| Q3 24 | — | $149.9M | ||
| Q2 24 | $-25.5M | $53.0M | ||
| Q1 24 | — | $119.1M |
自由现金流率BLRXNBIX
| Q4 25 | — | 47.9% | ||
| Q3 25 | — | 27.0% | ||
| Q2 25 | -914.1% | 13.0% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 37.5% | ||
| Q3 24 | — | 24.1% | ||
| Q2 24 | -472.8% | 9.0% | ||
| Q1 24 | — | 23.1% |
资本支出强度BLRXNBIX
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | 3.6% | 1.8% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | 1.1% | 2.0% | ||
| Q1 24 | — | 2.2% |
现金转化率BLRXNBIX
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 8.20× | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | -52.56× | 0.99× | ||
| Q1 24 | — | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLRX
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
